Phase 2Not yet recruiting

Low-Dose Naltrexone For ME/CFS: Dose-Finding

Low-dose Naltrexone (LDN) for the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Dose-Finding

Sponsor
University of Alabama at Birmingham (Academic or other)
Enrollment
75 planned
Conditions
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Interventions
Low-Dose Naltrexone, 1.5mg; Low-Dose Naltrexone, 3.0mg; Low-Dose Naltrexone, 4.5mg; Low-Dose Naltrexone, 6.0mg
Ages
adults, older adults
Registry
NCT07285473

Full record on ClinicalTrials.gov

From the registry

This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A remote trial approach is used, with eligibility open to the state of Alabama.

Primary outcomes

  • PROMIS Fatigue Short Form 7a

History

  1. Primary completion expected

  2. Started

  3. Last registry update

  4. Registered